معرفی
Cihangir Duy, PhD, MS, is an Assistant Professor at the Fox Chase Cancer Center, affiliated with the Cancer Epigenetics Institute, Greenberg Pancreatic Cancer Institute, and the Nuclear Dynamics and Cancer (NDC) program. His research is centered on epigenetic mechanisms in cancer, particularly in leukemia and lymphoma, with a focus on chromatin regulation, drug resistance, and therapeutic development.
His research interests include:
- Identifying drug survival mechanisms for novel therapeutic strategies
- Developing organoid models for precision medicine
- Regulating chromatin modifiers and enhancer-promoter interactions in hematopoietic cells
- Applying systems biology to understand epigenetic plasticity and epigenome regulation
The recent publications of Dr. Duy span high-impact journals such as Nature Immunology, Cancer Discovery, Cell, and Cancer Cell, reflecting a strong trend in understanding epigenetic dysregulation in hematologic malignancies. His work frequently explores mechanisms of therapy resistance, including dormancy, senescence, and metabolic adaptation, with a focus on targets like BCL6, LSD1, and MLL. His research integrates molecular biology, epigenomics, and translational approaches to develop precision therapies.
Scientific awards and recognitions include:
- American Society of Hematology 2023 Scholar Award
- V Scholar Award for studying DNA methylation in dormant leukemia cells
- Grant to investigate LSD1 inhibitors in dormant leukemia cells
Dr. Duy has been involved in significant research funding and collaborations, particularly in studying the persistence of leukemia cells after chemotherapy and the role of epigenetic regulators in tumor survival. His work has been highlighted in multiple press releases and media outlets, including Targeted News Service and India Pharma News, underscoring its clinical relevance and impact.
He is actively involved in cutting-edge research, with recent and upcoming publications in 2025, indicating ongoing leadership in the field of cancer epigenetics and therapy resistance.
